Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "What are the challenges of translating positive trial results in severe sepsis into clinical practice"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: What are the challenges of translating positive trial results in severe sepsis into clinical practice? | Available online http ccforum.eom content 6 3 271 Meeting report What are the challenges of translating positive trial results in severe sepsis into clinical practice A media roundtable debate 18 March 2002 Brussels Belgium Jonathan Ball Lecturer in Intensive Care Medicine Department of Anaesthesia Intensive Care St George s Hospital Medical School University of London London UK Correspondence Jonathan Ball jball@sghms.ac.uk Published online 1 May 2002 Critical Care 2002 6 271-274 2002 BioMed Central Ltd Print ISSN 1364-8535 Online ISSN 1466-609X Abstract The clinical syndrome of sepsis is common increasing in incidence and responsible for as many deaths annually as ischaemic heart disease. Two recent interventional trials have demonstrated that early recognition and intervention can result in dramatic reductions in acute 28-day mortality. This roundtable discussion was convened to identify ways in which these recent advances could be translated into clinical practice. The first obstacle surrounds the woolly and confusing terminology surrounding sepsis with the systemic inflammatory response syndrome SIRS model largely discredited. Overcoming this should facilitate wider recognition not only among health care providers in particular those working in acute specialties outside intensive care units ICUs but also politicians and the general public. Such education is vital successfully implemented. if early recognition and intervention are to be Keywords health resources sepsis This open discussion was arranged to raise awareness of the common clinical syndrome of sepsis and the apparent paradox between the successful development of the first modifying agent for this syndrome - recombinant human activated protein C rhAPC - and a perception that there may be slow uptake of its use by clinicians. The participants were as follows see the appendix for affiliation details and research activities Jean-Louis Vincent Antonio Artigas Jan Bakker Tony Sherry and Michele Schroeder.